The article focuses on several landmark clinical trials on the clinical management of patients with atrial fibrillation (AF). One of the main goals in the treatment of AF is minimizing recurrence of the arrhythmia. Small trials suggested that blockade of the renin-angiotensin system has positive effects on the pathophysiology of AF. A randomised controlled trial evaluated whether irbesartan would cut the risk of cardiovascular events in AF patients.